Publications

Trends in use of poly (ADP-ribose) polymerase inhibitor (PARPi) in ovarian cancer

Cancer Epidemiol.
Dottino JA, Baumann KE, Esselen KM, Costa R, Argetsinger S, Ross-Degnan D, Wagner AK.

Assessment of Oral Anticancer Medicines in Pediatric Patients before the Research to Accelerate Cures and Equity (RACE) Act, 2007-2021

J Pediatr.
Shahzad M, DuBois SG, Costa R, Argetsinger S, Ross-Degnan D, Bourgeois FT, Wagner AK.

Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study

PLoS Med.
McGonigle R, Naci H, Siebert M, Ouvina M, Gutiérrez-Sacristán A, Wagner AK, Bourgeois FT.

Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation

BMJ Med.
Naci H, Shahzad M, Murphy P, Zhang Y, Costa R, Ross JS, Wagner AK.

Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005–2022: an observational study

BMJ Evidence-Based Medicine
Yichen Zhang, Huangqianyu Li, Jinyu Chen, Huseyin Naci, Anita K Wagner, Luwen Shi, Xiaodong Guan

Reporting of Clinical Trial Uncertainties With New Cancer Drugs in Journal Publications and Clinical Guidelines

JAMA
Cherla A, Wagner AK, Wouters OJ, Woloshin S, Davis C, Mossialos E, Naci H

Threats of Weather Disasters for Drug Manufacturing Facilities in the US

JAMA
Shahzad M, Nogueira LM, Wagner A.

Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis

The Lancet. Oncology
Zhang Y, Chen D, Fu M, Shi L, Naci H, Wagner AK, Ross JS, Guan X

More employers offer preventive drug lists over time

The American Journal of Managed Care
Wagner AK, Argetsinger S, Lakoma M, Clemenzi J, Zhang F, Wharam JF, Ross-Degnan D

Preventive Drug Lists Reduce Income-Related Disparities in Medication Adherence Over 2 Years: A Natural Experiment for Translation in Diabetes (NEXT-D) Study

Medical Care
Ross-Degnan D, Argetsinger S, Lu CY, Wagner A, Lakoma M, Zhang F, Wharam JF.

New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019-22.

Health Aff (Millwood)
Cherla A, Woloshin S, Wagner AK, Wouters OJ, Davis C, Mossialos E, Naci H

Communication of uncertainties about recent cancer drugs in large language models

Clinical Oncology
Avi Cherla, Huseyin Naci, Steven Woloshin, Anita Katharina Wagner, and Mei-Sing Ong

Costs of ovarian cancer care since the introduction of poly (ADP-ribose) polymerase inhibitors (PARPis).

Clinical Oncology
Katherine Baumann, Katharine Esselen, Joseph Dottino, Rebecca Costa, Stephanie Argetsinger, Dennis Ross-Degnan, and Anita Katharina Wagner

Ovarian cancer biomarker testing over time in the era of PARP inhibitors

Gynecologic Oncology
Joseph Dottino, Stephanie Argetsinger, Rebecca Costa, Kate Esselen, Dennis Ross-Degnan, Anita Wagner

Patients deserve better information on new drugs.

BMJ
Davis C, Wagner AK, Mintzes B, Scowcroft H, Woloshin S, Naci H

Financial toxicity of withdrawn poly (ADP-ribose) polymerase inhibitor indications for ovarian cancer.

Value Health
Dottino JA, Esselen KM, Costa R, Argetsinger S, Shahzad M, Ross-Degnan D, Wagner AK

Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway.

J Pharm Policy Pract
Shahzad M, Naci H, Esselen KM, Dottino JA, Wagner AK

Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis.

Lancet Oncol
Naci H, Zhang Y, Woloshin S, Guan X, Xu Z, Wagner AK

Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020.

Lancet Reg Health West Pac
Wei Y, Zhang Y, Xu Z, Wang G, Zhou Y, Li H, Shi L, Naci H, Wagner AK, Guan X

Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015-2021.

BMJ Glob Health
Zhou Y, Naci H, Chen D, Bai L, Shi L, Guan X, Wagner AK